

## INDEX

|   |       |
|---|-------|
| <b><i>Certificate - 1</i></b>             | i     |
| <b><i>Certificate - 2</i></b>             | ii    |
| <b><i>Declaration</i></b>                 | iii   |
| <b><i>Preface</i></b>                     | iv    |
| <b><i>Acknowledgements</i></b>            | vi    |
| <b>Appendix- I: List of Abbreviations</b> | xiii  |
| <b>List of Tables</b>                     | xviii |
| <b>List of Figures</b>                    | xix   |

## CHAPTER I

|  |    |
|--|----|
| <b>1. Introduction</b>                                       | 1  |
| <b>1.1. Inflammation</b>                                     | 1  |
| <b>1.1.1. Causes of inflammation</b>                         | 1  |
| <b>1.1.2. Symptoms of inflammation</b>                       | 2  |
| <b>1.1.3. Classification of inflammation</b>                 | 2  |
| <b>1.1.3.1. Acute inflammation</b>                           | 3  |
| <b>1.1.3.2. Chronic inflammation</b>                         | 3  |
| <b>1.2. Janus kinase (JAK)</b>                               | 13 |
| <b>1.2.1. Structure of JAK protein and STAT protein</b>      | 14 |
| <b>1.2.2. Binding of JAK protein with different cytokine</b> | 16 |

|                   |  |    |
|-------------------|--|----|
| 1.2.3.            | The clinical significance for targeting JAK3   | 17 |
| 1.2.4.            | Mechanism of action of JAK-STAT pathway  | 17 |
| 1.2.5.            | Regulation of JAK-STAT pathway   | 19 |
| 1.2.6.            | JAK inhibitors   | 20 |
| 1.3               | Objectives   | 27 |
| 1.4.              | Design strategy  | 27 |
| <b>CHAPTER II</b> |  | 30 |
| 2.                | <b>Design and synthesis of compounds modified at 2<sup>nd</sup> position of Diamino pyrimidine</b>           | 30 |
| 2.1.              | Chemistry  | 31 |
| 2.1.1.            | Materials and methods  | 31 |
| 2.1.2.            | Importance of Diamino pyrimidine (DAP) in biological system  | 32 |
| 2.1.2.1.          | Biological importance  | 32 |
| 2.1.2.2.          | Possible routes for the synthesis of DAP   | 35 |
| 2.1.3.            | Synthesis of intermediates for R <sub>1</sub> substitution   | 38 |
| 2.1.4.            | General procedure for the synthesis of title compounds <b>41a-r</b>  | 56 |
| 2.1.5.            | List of R <sub>1</sub> substituent at 2 <sup>nd</sup> position of pyrimidine derivatives                     | 60 |
| 2.1.6.            | Spectral data of compounds <b>41a-r</b>  | 61 |
| 2.2.              | <i>In-vitro</i> JAK3 inhibitory activity data of pyrimidine derivatives modified at 2 <sup>nd</sup> position | 73 |

|                    |  |     |
|--------------------|--|-----|
| 2.3.               | Conclusion   | 76  |
| <b>CHAPTER III</b> |  | 78  |
| 3.                 | <b>Design and synthesis of compounds modified at 4<sup>th</sup> position of Diamino pyrimidine</b>           | 78  |
| 3.1.               | Chemistry  | 78  |
| 3.1.1.             | Materials and methods  | 78  |
| 3.1.2.             | General procedure for the synthesis of compounds <b>48a-v</b>  | 79  |
| 3.1.3.             | List of R <sub>2</sub> substituent at 4 <sup>th</sup> position of pyrimidine derivatives                     | 84  |
| 3.1.4.             | Spectral data of compounds <b>48a-v</b>  | 85  |
| 3.2.               | <i>In-vitro</i> JAK3 inhibitory activity data of pyrimidine derivatives modified at 4 <sup>th</sup> position | 98  |
| 3.3.               | Conclusion   | 101 |
| <b>CHAPTER IV</b>  |  | 103 |
| 4.                 | <b>Design and synthesis of compounds modified at 5<sup>th</sup> position of Diamino pyrimidine</b>           | 103 |
| 4.1.               | Chemistry  | 103 |
| 4.1.1.             | Materials and methods  | 103 |
| 4.1.2.             | General procedure for the synthesis of compounds <b>54a-m</b>  | 104 |
| 4.1.3.             | Procedure for the synthesis of <b>55</b> and <b>56</b>   | 108 |
| 4.1.4.             | List of R <sub>3</sub> substituent at 5 <sup>th</sup> position of pyrimidine derivatives                     | 110 |

|                  |  |     |
|------------------|--|-----|
| <b>4.1.5.</b>    | Spectral data of compounds <b>54a-m</b> , <b>55</b> and <b>56</b>  | 111 |
| <b>4.2.</b>      | <i>In-vitro</i> JAK3 inhibitory activity data of pyrimidine derivatives modified at 5 <sup>th</sup> position                 | 120 |
| <b>4.3.</b>      | Conclusion   | 123 |
| <b>CHAPTER V</b> |  | 124 |
| <b>5.</b>        | <b>Detailed biological evaluation of selected potent JAK inhibitors (41k and 48I)</b>  | 124 |
| <b>5.1.</b>      | Kinome selectivity profile of <b>48I</b> ( <i>In-vitro</i> )   | 124 |
| <b>5.2.</b>      | JAKs isoform selectivity   | 126 |
| <b>5.3.</b>      | JAK cellular assay using human peripheral blood mononuclear cells  | 128 |
| <b>5.4.</b>      | <i>Ex-vivo</i> studies: Liver microsomal study, CYP inhibition study, hERG inhibition study and Plasma protein binding study | 130 |
| <b>5.5.</b>      | Pharmacokinetic study of <b>41k</b> , <b>48I</b> and Tofacitinib in C57 mice   | 132 |
| <b>5.6.</b>      | <i>In-vivo</i> efficacy studies with compound <b>48I</b> and std (Tofacitinib)   | 133 |
| <b>5.6.1.</b>    | Anti-arthritic efficacy test compound in AIA rat model   | 134 |
| <b>5.6.2.</b>    | Anti-arthritic efficacy test compound in CIA mice model  | 135 |
| <b>5.7.</b>      | Safety pharmacology study of <b>48I</b>  | 137 |
| <b>5.8.</b>      | Docking study of compound <b>48I</b>   | 139 |
| <b>5.9.</b>      | Conclusion   | 142 |
| <b>6.</b>        | <b>Overall Summary and Future plans</b>  | 144 |
| <b>7.</b>        | <b>References</b>  | 150 |

|   |            |
|---|------------|
| <b>8. Appendix-II: Spectra (<math>^1\text{H}</math> NMR, <math>^{13}\text{C}</math> NMR, ESI-MS, UPLC / HPLC)</b> | <b>164</b> |
| <b>9. Publications and Posters</b>  | <b>221</b> |